Genmab has entered an agreement to grant Gilead an exclusive license and an option on a second exclusive license to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV. Genmab will receive an upfront payment of $5 million from Gilead. Genmab is entitled to potential development, regulatory and sales milestones of up to $277 million for the first product and further milestones for subsequent products. In addition, Gen...